Physician

Renuka Borra, M.D.

According to 2025 Medicare claims, Renuka Borra, M.D. (NPI: 1386686558) practices hematology/oncology in the Odessa, TX market, with the plurality of this provider's patient population coming from Ector, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 79761-5010. Borra is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Borra's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 497 traditional Medicare patients, billed 136,309 HCPCS/CPT codes, and received $1,630,267 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 1,309 prescription claims across 243 beneficiaries totaling $1,522,327 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 34 claims. Open Payments data shows 1 records totaling $18. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $750,172 to $1,522,327. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	508	165,316	$1,686,455
2016	688	187,303	$1,911,995
2017	698	110,842	$1,311,321
2018	556	95,202	$1,247,480
2019	563	92,137	$1,237,435
2020	458	94,799	$1,086,967
2021	412	72,993	$901,875
2022	486	111,013	$1,226,050
2023	497	119,242	$1,368,002
2024	497	136,309	$1,630,267

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	186	954	$750,172
2016	201	1,211	$843,320
2017	205	1,425	$1,127,858
2018	185	1,146	$761,139
2019	175	1,106	$544,356
2020	178	1,172	$763,567
2021	196	1,180	$924,302
2022	216	1,197	$1,363,291
2023	218	1,189	$1,477,742
2024	243	1,309	$1,522,327

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	44	221	$13,771
2016	35	169	$9,482
2017	N/R	53	$1,599
2018	N/R	N/R	N/R
2019	N/R	29	$2,234
2020	N/R	34	$2,409
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	157	247	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	204	424	$12
80053	Blood test, comprehensive group of blood chemicals	210	611	$10
36415	Insertion of needle into vein for collection of blood sample	265	1,130	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	261	1,018	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	28	749	$404,723
Tagrisso	Osimertinib Mesylate	13	390	$214,729
Xtandi	Enzalutamide	12	360	$159,778
Sorafenib	Sorafenib Tosylate	19	570	$57,020
Eliquis	Apixaban	48	1,740	$31,503

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$18	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Renuka Borra, M.D.?

Tedicare shows public-source Medicare data for Renuka Borra, M.D. (NPI 1386686558), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Renuka Borra, M.D. have ACO affiliation data?

Renuka Borra, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Renuka Borra, M.D.?

Renuka Borra, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Renuka Borra, M.D. have Open Payments data?

Renuka Borra, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.